Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	124
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	82
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	75
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	72
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	67
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	64
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	57
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	54
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	51
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	51
Ambient Air Pollution and Atherosclerosis: Recent Updates	48
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	46
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	46
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future	45
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	44
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	44
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	39
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	37
The Genetic Basis of Hypertriglyceridemia	36
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	36
The Emerging Specialty of Cardio-Rheumatology	34
RNA Silencing in the Management of Dyslipidemias	34
Inflammation in the Peri-ACS Period: Ready for Prime Time?	33
Percutaneous Coronary Interventions in Women	33

Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	32
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	30
mHealth Technology and CVD Risk Reduction	30
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	30
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	30
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	29
Lipoprotein(a): from Causality to Treatment	28
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	28
Hypertension in Women Across the Lifespan	28
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	28
The Role of Sleep in Cardiovascular Disease	28
Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions	28
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	27
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	27
Low LDL-C: Is It all Good News?	27
Transgender Cardiovascular Health: Practical Management for the Clinician	27
Update on Plant-Based Diets and Cardiometabolic Risk	26
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	26
Importance of Nutrition Security to CVD Prevention Efforts in the USA	24
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	24
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	24
COVID and Cardiovascular Disease: What We Know in 2021	23
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	23
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	22
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	22
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	22
Sustainable Diets for Cardiovascular Disease Prevention and Management	21
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	21
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	20
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	19
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	19
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	19
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	19
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	19
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	18
Lipoprotein (a): Recent Updates on a Unique Lipoprotein	18
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	18
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	18
Gene Regulatory Networks in Coronary Artery Disease	18
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	18
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	17
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	17
Cardiovascular Health and Disease in the Pakistani American Population	17
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	17
What Causes Premature Coronary Artery Disease?	16
Bempedoic Acid: for Whom and When	16
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	16

Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	15
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	15
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	15
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	15
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	15
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	15
Utility of FFRCT in Patients with Chest Pain	15
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Fixed Combination for the Treatment of Dyslipidaemia	14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	14
Apheresis: What Should a Clinician Know?	13
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	13
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	13
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	13
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	13
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	13
Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics	12
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	12
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	12
Statins and Inflammation	12
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	11
Obicetrapib—the Rebirth of CETP Inhibitors?	11
Managing Ischemic Heart Disease in Women: Role of a Women’s Heart Center	11
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia	11
Imaging Approaches to the Diagnosis of Vascular Diseases	11
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	11
HDL as a Treatment Target: Should We Abandon This Idea?	11
Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies	11
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	11
The TICE Pathway: Mechanisms and Potential Clinical Applications	11
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	11
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	10
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	10
CETP Inhibitors: Should We Continue to Pursue This Pathway?	10
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	10
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	10
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	10
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	10
How to Handle Elevated Triglycerides: Life after PROMINENT	10
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	10
An Update on Nutrition Guidance for Cardiovascular Health	10
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	9
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention	9
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	9
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?	9
Dietary Influences on Atherosclerotic Cardiovascular Disease Risk	9
Gene Editing for the Treatment of Hypercholesterolemia	9
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	9
Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors	8
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	8
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	8
Mechanisms Behind NAFLD: a System Genetics Perspective	8
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	8
Update on Sitosterolemia and Atherosclerosis	8
Family Meals and Cardiometabolic Risk Factors in Young Children	8
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?	8
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	8
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	8
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	8
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	8
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	8
More than Just a Monolayer: the Multifaceted Role of Endothelial Cells in the Pathophysiology of Atherosclerosis	8
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	8
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	7
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	7
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	7
The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia	7
Health Literacy is Essential to ASCVD Prevention in Youth	7
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	7
The Role of Coronary Artery Calcium Testing for Value-Based Clinical Trials in Primary Prevention	7
Familial Combined Hyperlipidemia: Myth or Reality?	7
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	7
Coronary Microvascular Dysfunction: A Practical Approach to Diagnosis and Management	7
Inclisiran: How Widely and When Should We Use It?	7
Sodium and Health Outcomes: Ascertaining Valid Estimates in Research Studies	6

Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	6
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	6
Lipid Phenotypes and DNA Methylation: a Review of the Literature	6
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	6
Built Environment and Cardiovascular Diseases – Insights from a Global Review	6
Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors	6
Statin Intolerance: an Overview of US and International Guidance	6
Impact of Sex Differences on Lipids and Statin Utilization	6
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	6
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	6
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	6
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	6
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	6
Insight into the Mechanistic role of Colchicine in Atherosclerosis	6
Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context	6
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	6
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	6
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	5
Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries	5
Telomere Length: Implications for Atherogenesis	5
Medication Induced Dyslipidemia in Children	5
Homozygous Familial Hypercholesterolemia Treatment: New Developments	5
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	5
Lp(a): A Rapidly Evolving Therapeutic Landscape	5
Takotsubo Syndrome: Uncovering Myths and Misconceptions	5
Evolution of Coronary Calcium Screening for Assessment of Atherosclerotic Cardiovascular Disease Risk and Role in Preventive Cardiology	5
Novel Therapeutics for Familial Chylomicronemia Syndrome	5
Updates in Drug Treatment of Severe Hypertriglyceridemia	5
Coconut Oil and Cardiovascular Disease Risk	5
The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health	5
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?	5
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	5
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	5
Social Media and Cardiovascular Health: Implications for Women	5
The Role of Genetics in Advancing Cardiometabolic Drug Development	5
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	5
Saturated Fat and Cardiovascular Health: Phenotype and Dietary Factors Influencing Interindividual Responsiveness	5
Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia	5
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	5
Impact of Climate Change on Cardiovascular Health	5